Shares of Novartis (NYSE: NVS) rallied sharply on Tuesday, climbing 6.0% to $161.22 by mid-morning trading, after the company unveiled promising Phase III data for its experimental oral multiple sclerosis (MS) therapy, remibrutinib. The positive results are seen as a critical step in the Swiss pharmaceutical giant's strategy to counter the looming patent cliff that threatens several of its key revenue drivers.
The stock peaked at $163.57 earlier in the session, with trading volume reaching 2.35 million shares, according to Yahoo Finance. The surge reflects growing investor optimism that remibrutinib could become a significant growth asset, particularly as Novartis faces intensifying competition from generic versions of its heart failure drug Entresto, which saw a 51% decline in sales at constant currencies during the last quarter.
In the two pivotal trials, known as REMODEL-1 and REMODEL-2, remibrutinib met its primary endpoints, demonstrating a statistically significant reduction in annualized relapse rates compared to teriflunomide, the active comparator. The drug also showed superiority on key MRI-lesion metrics, which are important markers of disease activity in MS. While the company did not disclose specific relapse rates in the headline release, a favorable trend in disability progression was observed at three months, with the pooled analysis achieving nominal significance at the six-month mark.
The market's reaction was notably focused on Novartis, as shares of Sanofi (NASDAQ: SNY), which markets teriflunomide, edged up just 0.1%, while Biogen (NASDAQ: BIIB) slipped 0.2%. This suggests that investors view the data as a company-specific catalyst rather than a broader sector shift.
The trials enrolled approximately 2,000 participants, who were randomized to receive either 100 mg of remibrutinib or teriflunomide, with a double-blind treatment period extending up to 30 months. Novartis reported that no liver safety issues were identified, a key concern for oral MS therapies. Shreeram Aradhye, the company's chief development officer, described remibrutinib as a "high-efficacy oral therapy," and full findings are expected to be presented at the MSToronto2026 conference.
Remibrutinib is already approved under the brand name Rhapsido for chronic spontaneous urticaria (hives), with the U.S. Food and Drug Administration granting approval in September 2025 and European regulators following in April 2026. However, the drug's commercial potential in MS is far larger. In the second quarter, Rhapsido generated just $64 million in sales, a fraction of the revenue needed to fill the gap left by Entresto's decline.
The urgency is underscored by Novartis's overall financial performance. In Q2 2026, the company posted total sales of $14.41 billion, with growth clipped by 14 percentage points due to generic competition, while volume growth contributed 18 points. The company's MS franchise, led by the injectable Kesimpta, generated $1.42 billion in Q2 sales, up 32% at constant currencies. Remibrutinib, if approved for MS, could complement Kesimpta and capture patients seeking an oral alternative.
However, several hurdles remain. The company has not yet released absolute relapse rates, and further analysis could temper the initial enthusiasm. Pricing, reimbursement, and regulatory approvals are also key uncertainties. Novartis plans to submit global regulatory filings after the full congress presentation and investor call, and maintains its 2026 outlook of low-single-digit sales growth and a low-single-digit decrease in core profit.
Investors will be watching closely as more detailed data emerges, but Tuesday's move indicates that the market is beginning to price in a successful launch. The patent cliff is a formidable challenge, but remibrutinib's early promise offers a potential lifeline.
